The role of radiotherapy after prostatectomy is controversial. This paper tries to give some guidelines for everyday practice through an analysis of literature data.
Methods
The potential role of radiotherapy in the adjuvant and salvage setting is discussed. We also report and interpret available literature data for both settings.
Results
As regards an increase in or detectable prostate-specific antigen (PSA) after radical prostatectomy, about 40–50% of patients are rendered bNED with local salvage radiotherapy, but only 10–50% are long-term (5 years) biochemically controlled. A timely salvage treatment is crucial to optimize control probability. As regards adjuvant radiotherapy for undetectable postoperative PSA in patients at high risk of failure as judged on pathology, results are more encouraging. Recent data report bNED rates ≥70% at 5 years.
Conclusions
Although results are far from satisfactory, salvage radiotherapy should be considered for every patient with an increased or detectable PSA after surgery. Adjuvant radiotherapy seems preferable to salvage radiotherapy for patients at high (>30%) risk of failure.
PoundC.R., PartinA.W., EpsteinJ.I., WalshP.C.: Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am, 24: 395–406, 1997.
2.
ZinckeH., OesterlingJ.E., BluteM.L., BergstralhE.J., MyersR.P., BarrettD.M.: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol, 152: 1850–1857, 1994.
3.
TrapassoJ.G., deKernionJ.B., SmithR.B., DoreyF.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol, 152: 1821–1825, 1994.
4.
CatalonaW.J., SmithD.S.: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol, 152: 1837–1842, 1994.
5.
OhoriM., WheelerT.M., DunnJ.K., StameyT.A., ScardinoP.T.: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol, 152: 1714–1520, 1994.
6.
KattanM.W., WheelerT.M., ScardinoP.T.: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol, 17: 1499–1507, 1999.
7.
QuinnD.I., HenshallS.M., HaynesA.M., BrennerP.C., KoonerR., GolovskyD., MathewsJ., O'NeillG.F., TurnerJ.J., DelpradoW., FinlaysonJ.F., SutherlandR.L., GrygielJ.J., StrickerP.D.: Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol, 19: 3692–3705, 2001.
8.
PoundC.R., PartinA.W., EisenbergerM.A., ChanD.W., PearsonJ.D., WalshP.C.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591–1597, 1999.
9.
AmlingC.L., BergstralhE.J., BluteM.L., SlezakJ.M., ZinckeH.: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?J Urol, 165: 1146–1151, 2001.
10.
DiamandisE.P., YuH.: New biological functions of prostate-specific antigen?J Clin Endocrinol Metab, 80: 1515–1517, 1995.
11.
SchellhammerP.F., el-MahdiA.M., KubanD.A., WrightGLJr.: Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir. Urol Clin North Am, 24: 407–414, 1997.
12.
MorganB.R., TarterT.H.: Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. J Urol, 166: 2311–2312, 2001.
13.
DohertyA.P., BowerM., SmithG.L., MianoR., MannionE.M., MitchellH., ChristmasT.J.: Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer, 83: 1432–1436, 2000.
14.
ParkerC., WardeP., CattonC.: Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother Oncol, 61: 107–116, 2001.
15.
AnscherM.S.: Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen. Int J Cancer, 20;96: 91–93, 2001.
16.
ViciniF.A., ZiajaE.L., KestinL.L., BrabbinsD.S., StrombergJ.S., GonzalezJ.A., MartinezA.A.: Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology, 54: 111–117, 1999.
17.
PeschelR.E., RobnettT.J., HesseD., KingC.R., EnnisR.D., SchiffP.B., WilsonL.D.: PSA based review of adjuvant and salvage radiation therapy vs observation in postoperative prostate cancer patients. Int J Cancer, 90: 29–36, 2000.
18.
WeigelT., HinkelbeinW.: Radiotherapy after radical prostatectomy in patients with prostate-specific antigen elevation. Front Radiat Ther Oncol, 36: 35–42, 2002.
19.
SchildS.E., BuskirkS J., WongW.W., HalyardM.Y., SwansonS.K., NovickiD.E., FerrigniR.G.: The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol, 156: 1725–1729, 1996.
20.
FormanJ.D., MeetzeK., PontesE., WoodD.P.Jr., ShamsaF., RanaT., PorterA.T.: Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol, 158: 1436–1439, 1997.
21.
MorrisM.M., DallowK.C., ZietmanA.L., ParkJ., AlthausenA., HeneyN.M., ShipleyW.U.: Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys, 38: 731–736, 1997.
22.
CadedduJ.A., PartinA.W., DeWeeseT.L., WalshP.C.: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol, 159: 173–177, 1998.
23.
AnscherM.S., CloughR., DodgeR.: Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys, 48: 369–375, 2000.
24.
PisanskyT.M., KozelskyT.F., MyersR.P., HillmanD.W., BluteM.L., BuskirkS.J., ChevilleJ.C., FerrigniR.G., SchildS.E.: Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol, 163: 845–850, 2000.
25.
LeventisA.K., ShariatS.F., KattanM.W., ButlerE.B., WheelerT.M., SlawinK.M.: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol, 19: 1030–1039, 2001.
26.
ChooR., HrubyG., HongJ., HongE., DeBoerG., DanjouxC., MortonG., KlotzL., BhakE., FlavinA.: Positive resection margin and/or pathologie T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?Int J Radiat Oncol Biol Phys, 52: 674–680, 2002.
27.
KatzM.S., ZelefskyM.J., VenkatramanN.S., FuksZ., LeeH.J., HummerA., LeibelS.A.: Risk stratification predicts biochemical outcome ater salvage post-prostatectomy three-dimensional conformal radiation therapy. 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Int J Rad Oncol Biol Phys, 51: 170, 2001.
28.
GrossfeldG.D., OlumiA.F., ConnollyJ.A., ChewK., GibneyJ., BhargavaV., WaldmanF.M., CarrollP.R.: Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol, 159: 1437–1443, 1998.
29.
ZagarsG.K., von EschenbachA.C., AyalaA.G., SchultheissT.E., ShermanN.E.: The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer, 68: 2370–2377, 1991.
30.
FuksZ., LeibelS.A., WallnerK.E., BeggC.B., FairW.R., AndersonL.L., HilarisB.S., WhitmoreW.F.: The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 1251 implantation. Int J Radiat Oncol Biol Phys, 21: 537–547, 1991.
31.
CoxJ.D., GallagherM.J., HammondE.H., KaplanR.S., SchellhammerP.F.: Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol, 17: 1155, 1999.
32.
ZinckeH., BergstralhE.J., Larson-KellerJ.J., FarrowG.M., MyersR.P., LieberM.M., BarrettD.M., RifeC.C., GonchoroffN.J.: Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer, 70: 311–323, 1992.
33.
SgrignoliA.R., WalshP.C., SteinbergG.D., SteinerM.S., EpsteinJ.I.: Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol, 152: 1077–1081, 1994.
34.
GolimbuM., ProvetJ., Al-AskariS., MoralesP.: Radical prostatectomy for stage D1 prostate cancer. Prognostic variables and results of treatment. Urology, 30: 427–435, 1987.
35.
SoergelT.M., KochM.O., FosterR.S., BihrleR., WahleG., GardnerT., JungS.H.: Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol, 166: 2198–2201, 2001.
36.
AnscherM.S., ProsnitzL.R.: Multivariate analysis of factors predicting local relapse after radical prostatectomy – possible indications for postoperative radiotherapy. Int J Radiat Oncol Biol Phys, 21: 941–947, 1991.
37.
FormentiS.C., LieskovskyG., SimoneauA.R., SkinnerD., GroshenS., ChenS.C., PetrovichZ.: Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy. J Urol, 155: 616–619, 1996.
MorganW.R., BergstralhE.J., ZinckeH.: Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology, 41: 113–120, 1993.
40.
LightnerD.J., LangeP.H., ReddyP.K., MooreL.: Prostate specific antigen and local recurrence after radical prostatectomy. J Urol, 144: 921–926, 1990.
41.
WiegelT., HinkelbeinW., SteinerU., MillerK.: Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol, 157: 965–966, 1997.
42.
LinkP., FreihaF.S., StameyT.A.: Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol, 145: 532–534, 1991.
43.
CoetzeeL.J., HarsV., PaulsonD.F.: Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology, 47: 232–235, 1996.
44.
MessingE.M., ManolaJ., SarosdyM., WildingG., CrawfordE.D., TrumpD.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341: 1781–1788, 1999.
45.
ZietmanA.L., PrinceE.A., NakfoorB.M., ShipleyW.U.: Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Urology, 49: 74–83, 1997.
46.
PollackA., SalemN., AshooriF., HachemP., SanghaM., von EschenbachA.C., MeistrichM.L.: Lack of prostate cancer ra-diosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys, 51: 1002–1007, 2001.
47.
DoT., DaveG., ParkerR., KaganA.R.: Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes. Int J Radiat Oncol Biol Phys, 50: 1220–1225, 2001.
48.
AnscherM.S.: Adjuvant therapy for pathologic stage C prostate cancer: a casualty of the PSA revolution?Int J Radiat Oncol Biol Phys, 34: 745–747, 1996.
49.
ZietmanA.L., CoenJ.J., ShipleyW.U., AlthausenA.F.: Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure. Urology, 42: 292–298, 1993.
50.
PetrovichZ., LieskovskyG., LangholzB., BochnerB., FormentiS., StreeterO., SkinnerD.G.: Adjuvant radiotherapy in patients with pathologic Stage C (pT3N0) adenocarcinoma of the prostate. Urology, 53: 1184–1193, 1999.
51.
YamadaA.H., LieskovskyG., PetrovichZ., ChenS.C., GroshenS., SkinnerD.G.: Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J Clin Oncol, 17: 277–285, 1994.
52.
PetrovichZ., LieskovskyG., LangholzB., FormentiS., BaertL., StreeterO., SkinnerD.G.: Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate. Int J Radiat Oncol Biol Phys, 40: 139–147, 1998.
53.
CornB.W., WinterK., PilepichM.V.: Does androgen suppression enhance the efficacy of postoperative irradiation?A secondary analysis of RTOG 85–31. Radiation Therapy Oncology Group. Urology, 54: 495–502, 1999.
54.
LeibovichB.C., EngenD.E., PattersonD.E., PisanskyT.M., AlexanderE.E., BluteM.L., BergstralhE.J., ZinckeH.: Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol, 163: 1178–1182, 2000.
55.
ValicentiR.K., GomellaL.G., IsmailM., MullhollandS.G., PetersenR.O., CornB.W.: Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control. Cancer, 82: 1909–1914, 1998.
56.
TaylorN.A., KellyJ.F., KubanD.A., BabaianR.J., PistersL.L., PollackA.: Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Int J Rad Oncol Biol Phys, 51: 317, 2001.
57.
CozzariniC., CeresoliG.L., BolognesiA., BertiniR., Da PozzoL., FiorinoC., CattaneoM., VillaE.: Importance of time to radiotherapy and lack of evidence for the use of adjuvant androgen ablation in 165 node-negative prostate cancer treated with radical prostatectomy and adjuvant radiotherapy. 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Int J Rad Oncol Biol Phys, 51: 281–282, 2001.
58.
KattanM.W., WheelerT.M., ScardinoP.T.: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol, 17: 1499–1507, 1999.
59.
GraefenM., KarakiewiczP.I., CagiannosI., KleinE., KupelianP.A., QuinnD.I., HenshallS.M., GrygielJ.J., SutherlandR.L., StrickerP.D., de KernionJ., CangianoT., SchroderF.H., WildhagenM.F., ScardinoP.T., KattanM.W.: Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol, 20: 951–956, 2002.
60.
PaulsonD.F.: Impact of radical prostatectomy in the management of clinically localized disease. J Urol, 152: 1826–1830, 1994.
61.
EpsteinJ.I.: Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am, 23: 651–663, 1996.
62.
KupelianP.A., KatcherJ., LevinH.S., KleinE.A.: Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys, 37: 1043–1052, 1997.
63.
PollackA., SmithL.G.: Adjuvant external beam radiation therapy postprostatectomy. In: Prostate cancer: principles and practice, KantoffP.W., CarrollP.R., D'AmicoA.V. (Eds), Lippincott Williams and Wilkins, Philadelphia, 2002.
64.
WiegelT., BresselM., CarlU.M.: Adjuvant radiotherapy following radical prostatectomy-results of 56 patients. Eur J Cancer, 31A: 5–11, 1995.
65.
GrossfeldG.D., TigraniV.S., NudellD., RoachM.3rd, WeinbergV.K., PrestiJ.C.Jr., SmallE.J., CarrollP.R.: Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol, 164: 93–99, 2000.
66.
HanM., PartinA.W., PoundC.R., EpsteinJ.I., WalshP.C.: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am, 28: 555–565, 2001.
67.
HanM., PoundC.R., PotterS.R., PartinA.W., EpsteinJ.I., WalshP.C.: Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. J Urol, 165: 864–866, 2001.
68.
LightnerD.J., LangeP.H., ReddyP.K., MooreL.: Prostate specific antigen and local recurrence after radical prostatectomy. J Urol, 144: 921–926, 1990.
69.
SchildS.E., WongW.W., GradoG.L., BuskirkS.J., RobinowJ.S., FrickL.M., FerrigniR.G.: Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc, 69: 613–619, 1994.
70.
ValicentiR.K., GomellaL.G., IsmailM., MulhollandS.G., PetersenR.O., CornB.W.: Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Int J Radiat Oncol Biol Phys, 42: 501–506, 1998.
71.
ZagarsG.K., PollackA., von EschenbachA.C.: Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology, 58: 233–239, 2001.
72.
EulauS.M., TateD.J., StameyT.A., BagshawM.A., HancockS.L.: Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys, 41: 735–740, 1998.
73.
LauW.K., BergstralhE.J., BluteM.L., SlezakJ.M., ZinckeH.: Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol, 167: 117–122, 1998.
